Understanding the Impact of Respiratory Syncytial Virus (RSV)
Learn about the impact of Respiratory Syncytial Virus (RSV) on different age groups and the importance of public health awareness and prevention. Discover the symptoms, risk factors, and preventive strategies to protect vulnerable individuals from severe complications. Take proactive steps to minimize transmission and promote public health and well-being.
New RSV Vaccine Offers Hope in Fighting Common Childhood Virus
Discover the latest advancements in combating RSV with the introduction of a new vaccine. Healthcare professionals are exploring how to incorporate this promising vaccine into clinical practice to prevent the spread and reduce the severity of this common viral infection. Stay informed on the evolving landscape of managing respiratory infections and enhance your ability to deliver high-quality care.
Pfizer’s RSV vaccine shows promising results in older adults
Pfizer’s Abrysvo vaccine has shown durable protection for older adults against respiratory syncytial virus, with consistent efficacy across two full seasons. Initial data on more than 37,000 participants indicates 77.8% effectiveness against severe illness after the second season, down from 88.9% after one season. The vaccine also demonstrated consistent efficacy against RSV A and RSV B, with no new adverse events reported after the two seasons.